Vaxart, Inc.

NASDAQ:VXRT

Biotechnology

Healthcare
$0.53 -1.75%

-$0.01 today

Market cap
$129.30M
Beta
1.09
P/E (TTM)
3.6
EPS (TTM)
$0.15
52W Low $0.26High $0.84

Volume 0.12M

Average 0.41M

VXRT Account Payables

Amounts the company owes suppliers for goods and services received.

Vaxart, Inc.NASDAQ: VXRT

Account Payables · Q1 FY2026 · quarter ended Mar 2026

Account payables rises 45.5% from a year ago

Account payables stood at $24.19M at the end of Q1 FY2026, up 45.5% from a year earlier and up 12.5% from the prior quarter. Over 3 fiscal years it compounded at +57.4% a year.

Context

  • Account payables amounted to 13.4% of total assets at the end of Q1 FY2026, up 3.0 pp from a year earlier.
  • Account payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether account payables keeps rising in the next quarterly balance sheet after a +45.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$24.19M+12.5% QoQ
Last fiscal yearDec 2025
$21.5M+208.7% YoY
Year agoMar 2025
$16.62M+45.5% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+45.5%——
1 year+208.7%——
3-year CAGR+57.4%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
21.5M USD
Year-over-year change
+208.7%
4-year CAGR
+53.5%

Account Payables vs competitors

How VXRT compares with its peers on the latest reported figures

  • VXRT's Mar 2026 account payables of $24.19M is the highest of the 10 companies compared; the peer median is $2.3M.
  • Its year-over-year change of +45.5% is the 3rd highest of 10, against a peer median of -38.3%.
  • Account payables amounts to 13.4% of total assets for VXRT, versus a peer median of 1.7%.
VXRT Competitors Peer median
Account Payables for VXRT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VXRTVaxart, Inc.Mar 2026$24.19M +45.5%+57.4%13.4%
FBIOFortress Biotech, Inc.Mar 2026$14.14M -49.2%-37.1%4.0%
IMUXImmunic, Inc.Mar 2026$10.51M +90.9%+33.3%5.5%
RLMDRelmada Therapeutics, Inc.Mar 2026$5.73M +353.1%-33.2%2.4%
CBUSCibus, Inc.Mar 2026$5.41M -20.2%+187.4%1.7%
TCRXTScan Therapeutics, Inc.Mar 2026$2.3M -53.6%-24.7%1.1%
PMVPPMV Pharmaceuticals, Inc.Mar 2026$1.63M -54.6%+1.7%1.7%
ACRVAcrivon Therapeutics, Inc. Common StockMar 2026$1.16M -68.5%+36.1%1.1%
UNCYUnicycive Therapeutics, Inc.Mar 2026$1.01M -18.9%-29.1%1.6%
CAMPCAMP4 Therapeutics CorporationMar 2026$863K -38.3%—0.8%
Peer median (excluding VXRT) $2.3M-38.3%-11.5%1.7%

Competitors are the stored peer set for VXRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents143.75M44.01M34.76M25.23M53.81M
Short-term Investments22.74M49.7M4.96M26.49M9.99M
Net Receivables71K20K3.01M11.97M51.35M
Inventory00000
Other Current Assets02M333K318K667K
Total Current Assets169.17M99.45M45.54M68.26M136.12M
Property, Plant & Equipment (Net)19.77M41.3M36.57M29.11M16.87M
Goodwill4.51M4.51M4.51M4.51M4.51M
Intangible Assets10.62M5.02M4.29M3.56M2.83M
Long-term Investments16.21M0000
Tax Assets00000
Other Non-current Assets890K3.57M926K60.96M25.76M
Total Non-current Assets52M54.4M46.29M98.13M49.96M
Total Assets221.17M153.85M91.83M166.39M186.08M
Account Payables3.87M5.51M1.58M6.96M21.5M
Short-term Debt836K95K3.8M4.06M0
Tax Payables00000
Deferred Revenue000013.02M
Other Current Liabilities12M065.4M5.63M
Total Current Liabilities10.78M17.92M13.72M90.88M86.75M
Long-term Debt10.69M5.62M2.62M1.7M0
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00002.02M
Other Non-current Liabilities171K231K293K439K3.5M
Total Non-current Liabilities22.85M25.33M20.3M16.59M11.53M
Total Liabilities33.64M43.25M34.03M107.46M98.28M
Common Stock13K13K15K23K24K
Retained Earnings(219.35M)(327.11M)(409.57M)(476.52M)(460.2M)
Accumulated OCI(74K)(299K)(1K)4K(3K)
Other Stockholders Equity(0)0000
Minority Interest00000
Total Equity187.53M110.6M57.81M58.93M87.8M
Total Debt24.53M27.42M26.51M23.28M8.99M
Net Debt(119.22M)(16.59M)(8.24M)(1.95M)(44.83M)

Vaxart, Inc.

NASDAQ:VXRT

Intrinsic Alpha fair value

Locked

Current Price

$0.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.